Clinical Trials | February 17, 2026
Roche’s Gazyva hits major milestone in rare kidney disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Duvakitug was well tolerated and safety was consistent with the induction study
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Subscribe To Our Newsletter & Stay Updated
